Multiple myeloma - lenalidomide: review decision - November 2012 information
History
A list of downloadable documents created during development.
Background information
-
-
Appendix A: GE Decision paper
-
-
Multiple myeloma - lenalidomide: review proposal - March 2012 information
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 148 KB)
-
TA171 Multiple myeloma - lenalidomide: review update - November 2011 information
-
TA171 Multiple myeloma - lenalidomide: review update - January 2011 information
Multiple myeloma - lenalidomide: final appraisal determination
-
Multiple myeloma - lenalidomide: final appraisal determination information
-
Multiple myeloma - lenalidomide: final appraisal determination
-
Multiple myeloma - lenalidomide: final appraisal determination (PDF 132 KB)
-
Response to consultee, commentator and public comments on the ACD and comments from website consultation
-
Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) issued October 2008
-
-
Response to consultee, commentator and public comments on the second Appraisal Consultation Document (ACD) issued January 2009
-
-
Letter from the Department of health RE: Patient Access Scheme for lenalidomide for the treatment of multiple myeloma
-
-
Letter from Celgene sent on 26th February 2009
-
-
Consultee and commentator comments on the ACD
-
Celgene
-
-
Department of Health
-
-
Janssen-Cilag
-
-
Macmillan Cancer Relief
-
-
Myeloma UK
-
-
Royal College of Nursing
-
-
Royal College of Pathologists
-
-
Royal College of Physicians on behalf of NCRI/RCP/RCR/ACP/JCCO
-
Royal College of Physicians on behalf of NCRI/RCP/RCR/ACP/JCCO (PDF 35 KB)
-
Sandwell PCT
-
-
UK Myeloma Forum and British Society for Haematology
-
UK Myeloma Forum and British Society for Haematology (PDF 14 KB)
-
Public comments on the ACD
-
Multiple myeloma - lenalidomide: appraisal consultation document 2
-
Multiple myeloma - lenalidomide: appraisal consultation document 2
-
Multiple myeloma - lenalidomide: appraisal consultation document 2 information
-
Multiple myeloma - lenalidomide: comments on the ACD issued in October 2008
-
Extra analysis
-
Addendum to the ERG report
-
-
Addendum to the pre-meeting briefing: end of life - a quantitative exploration
-
Addendum to the pre-meeting briefing: end of life - a quantitative exploration (PDF 24 KB)
-
Non-manufacturer comments on the ACD issued in October 2008
-
Department of Health
-
-
Janssen-Cilag
-
-
Macmillan Cancer Support
-
-
Myeloma UK, Leukaemia CARE, Leukaemia Research and the Rarer Cancers Forum
-
Myeloma UK, Leukaemia CARE, Leukaemia Research and the Rarer Cancers Forum (PDF 66 KB)
-
Royal College of Nursing
-
-
Royal College of Physicians, Medical Oncology Joint Special Committee
-
Royal College of Physicians, Medical Oncology Joint Special Committee (PDF 22 KB)
-
Royal College of Pathologist
-
-
Sandwell PCT
-
-
UK Myeloma Forum and British Society for Haematology
-
UK Myeloma Forum and British Society for Haematology (PDF 17 KB)
-
Welsh Assembly Government
-
-
Manufacturer comments on the ACD issued in October 2008
-
Celgene response to ACD
-
-
Celgene response to ERG lenalidomide report
-
-
Letter to DH regarding proposed patient access scheme
-
Letter to DH regarding proposed patient access scheme (PDF 139 KB)
-
Response to questions from NICE on ACD comments
-
-
NICE letter to Celgene requesting clarification on their ACD response
-
NICE letter to Celgene requesting clarification on their ACD response (PDF 28 KB)
-
Public comments on the ACD issued in October 2008
-
Letters
-
-
Emails
-
-
Web comments
-
-
Letter to NICE from the Department of Health RE: Patient Access Scheme for lenalidomide for the treatment of multiple myeloma
-
Multiple myeloma - lenalidomide: appraisal consultation
-
Multiple myeloma - lenalidomide: appraisal consultation
-
Multiple myeloma - lenalidomide: appraisal consultation document information
-
Multiple myeloma - lenalidomide: evaluation report
-
Multiple myeloma - lenalidomide: pre-meeting briefing
-
Multiple myeloma - lenalidomide: pre-meeting briefing (PDF 133 KB)
-
Multiple myeloma - lenalidomide: evidence review group report
-
Multiple myeloma - lenalidomide: evidence review group report (PDF 997 KB)
-
Non-manufacturer submissions
-
Myeloma UK
-
-
Royal College of Nursing
-
-
Royal College of Physicians (on behalf of the NCRI, RCP, RCR, ACP and JCCO)
-
Royal College of Physicians (on behalf of the NCRI, RCP, RCR, ACP and JCCO) (PDF 36 KB)
-
Royal College of Pathologists
-
-
UK Myeloma Forum and British Society For Haematology
-
UK Myeloma Forum and British Society For Haematology (PDF 125 KB)
-
Manufacturer submission
-
Celgene
-
-
NICE request for clarification
-
-
Response from Celgene to request for clarification: Additional information: Part 1
-
Response from Celgene to request for clarification: Additional information: Part 1 (PDF 26 KB)
-
Response from Celgene to request for clarification: Additional information: Part 2
-
Response from Celgene to request for clarification: Additional information: Part 2 (PDF 17 KB)
-
Multiple myeloma - lenalidomide: Response from Celgene to request for clarification
-
Multiple myeloma - lenalidomide: Response from Celgene to request for clarification (PDF 288 KB)
-
Expert written personal statements
-
Brown
-
-
Cavenagh
-
-
Low
-
-
Schey
-
Multiple myeloma - lenalidomide: final scope
-
Multiple myeloma - lenalidomide: final scope
-
Multiple myeloma - lenalidomide: draft scope (pre-referral)
-
Multiple myeloma - lenalidomide: draft scope (pre-referral)
-
Multiple myeloma - lenalidomide: draft scope (pre-referral) (PDF 34 KB)
Multiple myeloma - lenalidomide: response to comments on the draft scope (pre-referral)
-
Multiple myeloma - lenalidomide: response to comments on the draft scope (pre-referral)
-
Multiple myeloma - lenalidomide: response to comments on the draft scope (pre-referral) (PDF 147 KB)
Multiple myeloma - lenalidomide: provisional matrix of consultees and commentators
-
Multiple myeloma - lenalidomide: provisional matrix of consultees and commentators
-
Multiple myeloma - lenalidomide: provisional matrix of consultees and commentators (PDF 30 KB)
Multiple myeloma - lenalidomide: response to comments on provisional matrix of consultees and commentators
-
Multiple myeloma - lenalidomide: response to comments on provisional matrix of consultees and commentators
-